Opko Health Inc. (NASDAQ:OPK) is one of the best strong buy penny stocks to buy now. On July 31, Opko Health Inc. (NASDAQ:OPK) reported its fiscal Q2 2025 results, with consolidated total revenues for the quarter reaching $156.8 million compared to $182.2 million in the same quarter last year.
A doctor in scrubs discussing a patient’s test results with a small group of concerned family members.
Operating loss for the quarter was $60.0 million, down from $61.7 million in Q2 2024.
Revenue from products in its Pharmaceuticals segment underwent a slight growth to $40.7 million in Q2 2025 from $40.5 million in Q2 2024, reflecting increased sales volumes in certain international operations. These trends were partially offset by lowered sales in its Chilean subsidiary, primarily due to a mild winter cold and flu season and foreign currency impacts.
Revenue from services in the diagnostics segment dropped to $101.1 million in Q2 2025 compared to $129.4 million in the prior year period. Management attributed the decrease to lower clinical test volume principally as a result of the sale of certain BioReference assets.
Opko Health Inc. is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
